Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors

NCT03261011 is registered in ClinicalTrials.gov with Akesobio Australia Pty Ltd as lead sponsor.

NCT NCT03261011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03261011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
Lead sponsor
Akesobio Australia Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
October 3, 2017
Completion date
April 13, 2023
Enrollment
119 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer